Category: Nordisks
-
Medicare coverage of Novo Nordisk’s Wegovy could cost up to $145B annually
•
aprott/iStock via Getty Images Novo Nordisk’s (NVO) weight-loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries with obesity and cardiovascular disease, could cost the system up to $145 billion a year. If all eligible beneficiaries receive Wegovy If achieved, it would cost Medicare between $34 billion and $145…